Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07527130 · ClinicalTrials.gov registry record

C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

A clinical trial, sponsored by Mayo Clinic.

Not yet
Registry status
10
Enrollment target

NCT07527130: Clinical Trial study, sponsored by Mayo Clinic.

NCT07527130 is a clinical trial that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07527130 has not yet begun recruiting, sponsored by Mayo Clinic.

NOT YET RECRUITING
Registry status
10 participants
Enrollment target

Study Summary

The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.

Primary Outcome

Estimation of areas degree of neuroinflammation determined by the radiologist

Interventions

  • DRUG C11 ER176 Tracer

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2026-05
Est. Completion 2027-12
Mayo Clinic

2,844 total trials

What is known before NCT07527130 opens enrollment

NCT07527130 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which C11 ER176 Tracer is the first listed.

NCT07527130 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07527130 about?

NCT07527130 is a clinical study titled "C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome". The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.

What is the current status of trial NCT07527130?

This trial is currently not yet recruiting. The enrollment target is 10 participants. The study started on 2026-05. Estimated completion is 2027-12.

What interventions are being tested in trial NCT07527130?

The interventions under investigation include: C11 ER176 Tracer (DRUG).

Who is sponsoring clinical trial NCT07527130?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07527130, the US trial registry maintained by the National Library of Medicine. NCT07527130 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.